Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing
BCR-ABL1 compound mutations
BCR-ABL1T315I
CML
asciminib
drug combinations
hydroxyurea
leukemic stem cells
ponatinib
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
03
2021
accepted:
19
07
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
Ponatinib is a tyrosine kinase inhibitor (TKI) directed against BCR-ABL1 which is successfully used in patients with
Types de publication
Journal Article
Langues
eng
Pagination
4470-4484Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
K.V.G.: honoraria from Novartis, Incyte, BMS, Pfizer and AbbVie. K.B.: employment at Oncopeptides AB. T.L.: honoraria from Incyte, Pfizer, Angelini, Novartis, Bristol-Myers Squibb, and Amgen; research grants from Incyte and Novartis. J.M.: research grant and travel support from Novartis. W.R.S.: honoraria from AbbVie, Amgen, Astellas, Celgene, Daiichi Sankyo, Deciphera, Incyte, Jazz, Lipomed, Novartis, Pfizer und Thermo Fisher. P.V.: research funding and honoraria from Novartis and Incyte, and honoraria from BMS/Celgene, Blueprint, Pfizer, AOP Orphan. The other authors (Y.F., D.B., C.S., I.S., L.D.-S., G.E., M.S.-G.) have not disclosed conflicts of interest.
Références
Leuk Res. 2019 Mar;78:36-44
pubmed: 30711891
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Best Pract Res Clin Haematol. 2020 Sep;33(3):101194
pubmed: 33038988
J Clin Oncol. 2014 Feb 10;32(5):415-23
pubmed: 24297946
Oncotarget. 2016 Nov 22;7(47):78083-78094
pubmed: 27801667
N Engl J Med. 2019 Dec 12;381(24):2315-2326
pubmed: 31826340
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Haematologica. 2018 Jan;103(1):e10-e12
pubmed: 28983061
Br J Haematol. 2008 Jul;142(3):361-78
pubmed: 18540942
EBioMedicine. 2019 Dec;50:111-121
pubmed: 31761618
Blood. 2013 Jan 17;121(3):489-98
pubmed: 23223358
Front Oncol. 2021 Mar 16;11:642005
pubmed: 33796468
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Clin Cancer Res. 2008 Jul 15;14(14):4392-9
pubmed: 18628453
Leukemia. 2015 Sep;29(9):1823-31
pubmed: 26088952
Cancer Res. 2002 Dec 15;62(24):7149-53
pubmed: 12499247
Leukemia. 2007 May;21(5):926-35
pubmed: 17330101
J Biol Chem. 2010 Feb 12;285(7):5085-96
pubmed: 20007699
Leuk Res. 2020 Nov;98:106458
pubmed: 33096322
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):515-29
pubmed: 23890944
J Clin Invest. 2007 Sep;117(9):2562-9
pubmed: 17710227
Blood. 2006 Jun 1;107(11):4532-9
pubmed: 16469872
Oncotarget. 2018 Feb 3;9(17):13423-13437
pubmed: 29568367
J Med Chem. 2018 Sep 27;61(18):8120-8135
pubmed: 30137981
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Blood. 2015 Feb 5;125(6):901-6
pubmed: 25525119
Cancer Res. 2012 Oct 1;72(19):4890-5
pubmed: 23002203
Anticancer Agents Med Chem. 2019;19(13):1642-1650
pubmed: 31250767
Cancer Cell. 2002 Aug;2(2):117-25
pubmed: 12204532
Oncotarget. 2017 Apr 4;8(14):23061-23072
pubmed: 28416739
J Clin Oncol. 2009 Dec 10;27(35):6041-51
pubmed: 19884523
Nature. 2017 Mar 30;543(7647):733-737
pubmed: 28329763
Cancer Cell. 2019 Oct 14;36(4):431-443.e5
pubmed: 31543464
Leuk Res. 2019 Jun;81:102-104
pubmed: 30981418
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5
pubmed: 24550512
Semin Hematol. 2007 Jan;44(1 Suppl 1):S15-24
pubmed: 17292737
Drug Discov Today Technol. 2014 Mar;11:89-99
pubmed: 24847658
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
Lancet Haematol. 2015 Sep;2(9):e376-83
pubmed: 26436130
Leukemia. 2014 Apr;28(4):976-7
pubmed: 24170029
Onco Targets Ther. 2019 Jan 18;12:635-645
pubmed: 30705592
Chemotherapy. 2019;64(4):205-209
pubmed: 31825920
Blood Cancer J. 2021 Feb 9;11(2):16
pubmed: 33563899